Category Archives: Stem Cell Treatment


Lasers and Stem Cells Regrowing Teeth

Stem cells are the future of healthcare for the human race, as we've studied them more we've found out all the different ways that they could be used to take care of many of the problems facing people today, from baldness to Alzheimer's research, they've become the miracle cure that society has wanted to badly for so many years. (christianitytoday) The biggest problem people have had with stem cell treatment is that when it began the primary source of stem cells was via embryonic stem cells, this put the majority of people off the process as they weren't willing to support aborted embryos in order to progress medically. (frc) With the advancement in the process and the ability to generate stem cells from adult tissue the battle over the ethics of using said cells to treat the many illnesses and injuries that have embattled the human race for ages, making it more palatable for those who were once torn over the research. (childrenshospital) As the debate rages on over the benefits and risks of stem cell treatment the benefits keep growing and the negatives seem to be slowly passing by the wayside, as a result using stem cells to take care of our ailments is gaining steam and with any luck it'll change everything for the better. (nih)

One of the most common medical problems that has faced people since the begging of time is dental work, while we've made progress in this field we're still somewhat archaic in it as well, relying on drills and pliers to repair damage that has accrued over time. (acedentalresource) There have been tests in order to regrow teeth and surrounding tissue using stem cells for some time now, with positive results it's seemed that stem cell treatment would be the next step in taking care of our teeth and we would finally get past the need for dentures or implants, although the question is how long that may take. (reuters) Last year the move to regrow teeth saw an advancement through the use of stem cells that were derived from urine, not quite the process people want to envision the process happening but it seemed like the most likely way to avoid painful implants or terrible fitting dentures. (nydailynews) A new evolution seems to be on the horizon now using low level lasers and stem cells to regenerate teeth instead of having to replace them, this is a huge development and as someone with dental concerns myself and a severe phobia of dentists, I'm looking forward to the future on this one. (iflscience)

Excerpt from:
Lasers and Stem Cells Regrowing Teeth

How the rich try to buy eternal youth

NEW YORK (CNNMoney) The best kind of anti-aging treatment is inside ones own body, and the rich are taking advantage of it, exploring the latest research in new technologies, genome mapping and stem cell treatments.

Among them is Oracle billionaire Larry Ellison, a large investor of the Ellison Medical Foundation, which supports research exploring the biology that underlies aging and age-related diseases. And theres billionaire Peter Nygrd, who says he wants to live forever (or die trying), and has suggested hes found the keys to immortality in stem cell research.

Some doctors agree that stem cells are a key part of chasing youth.

If youre a wealthy guy and havent stored your stem cells, I think youre a total idiot, said Dr. Lionel Bissoon, a New York City physician who sees a number of stressed out, wealthy patients.

They usually come to him with similar problems: Fatigue, belly fat, erectile dysfunction, tiring very quickly all very common with my patients from Wall Street, Bissoon said. The short-term solution to those ailments, he says, is testosterone replacement which is relatively affordable at a few hundred dollars a pop and IV nutrition.

For the long term he recommends stem cell storage, which works as a sort of rainy day insurance. The cells are extracted, preferably when the patient is on the younger side around 30 is said to be a good age and can then be used to boost an immune system or help to rebuild damaged organs later.

Dr. Dipnarine Maharaj stores cells at his South Florida Bone Marrow Stem Cell Transplant Institute in Boynton Beach, Fla.

People are looking and finding ways to be able to help them to live longer to spend the money theyve earned, he said. They spend their retirement going doctor to doctor, and if we can find ways to prevent that it would be good. His clinic sees executives under a lot of stress, a fast way to damage any immune system.

He agrees that its important to store cells before they become irreparably damaged. To collect and store stem cells at his clinic costs $15,000 for the initial extraction, which includes a year of storage. After that, storage costs $50 per month.

Stem cells arent the only high-end solution.

View post:
How the rich try to buy eternal youth

Lung Institute Instrumental in Allowing Robert Ware to Get His Life Back

Tampa, FL (PRWEB) June 19, 2014

Located in Tampa, FL, Lung Institute was instrumental in allowing Robert Ware get his life back. Three months ago, Robert decided to take his health into his own hands and move ahead with stem cell treatment. Hundreds of people with lung disease have been treated with the companys innovative use of stem cells from the patients own body.

Stem cell therapy is a viable option for many people with lung disease, said Dr. Burton Feinerman, Medical Director of the Lung Institute. Our patients are breathing easier, walking further, and depending less on supplemental oxygen.

For Robert, 71, chronic obstructive pulmonary disease (COPD) was taking over his life. Over the past decade, this progressive lung disease diminished his quality of life and forced him away from the activities he used to love. Robert was unable to be outdoors, attend live music shows in the town squares and work on his yard and landscaping. A few months ago, Robert had a health scare that he thought was a heart attack. He was actually experiencing lung spasms and not receiving enough oxygen, often referred to as a COPD exacerbation.

COPD is not only the third leading cause of death in the United States, but is responsible for severely limiting sufferers quality of life. People with COPD often cant even walk to their mailbox without debilitating shortness of breath. For people without COPD, it is akin to breathing through a small straw while carrying out normal activities.

In Roberts case, his exacerbation caused him to look for alternatives to the traditional medications he had been taking. Robert and his wife decided stem cell therapy at the Lung Institute was the best option for him. Robert received autologous stem cell therapy, meaning stem cells from his own body were used to help cue natural healing processes for damaged lung tissue. After the minimally invasive, outpatient procedure, Robert returned home and was able to regain a substantial amount of his quality of life.

Before treatment, I was pretty much on oxygen all the time, said Robert. I couldnt do much without my oxygen. Today, Im doing just about anything I want to do.

Now, Robert no longer needs to pay someone to take care of his lawn. Robert is able to be outdoors, mow the grass, work around the house and go out with friends.

People are just amazed how well Im doing. Im probably 75% to what I was originally, 10 years ago, added Robert. I started getting better fast and my friends couldnt believe it. They were shocked. It was kind of funfeeling good, rather than being sick.

About Lung Institute At Lung Institute (LI), we are changing the lives of hundreds of people across the nation through the innovative technology of regenerative medicine. We are committed to providing patients a more effective way to address pulmonary conditions and improve quality of life. Our physicians, through their designated practices, have gained worldwide recognition for the successful application of revolutionary minimally invasive stem cell therapies. With over a century of combined medical experience, our doctors have established a patient experience designed with the highest concern for patient safety and quality of care. For more information, visit our website at LungInstitute.com, like us on Facebook, follow us on Twitter or call us today at 1-855-469-5864.

See the rest here:
Lung Institute Instrumental in Allowing Robert Ware to Get His Life Back

Can enough money buy you eternal youth?

NEW YORK (CNNMoney)

No need to go that far.

It turns out, the best kind of anti-aging treatment is inside one's own body, and the rich are taking advantage of it, exploring the latest research in new technologies, genome mapping and stem cell treatments.

Among them is Oracle billionaire Larry Ellison, a large investor of the Ellison Medical Foundation, which supports research exploring the biology that underlies aging and age-related diseases. And there's billionaire Peter Nygrd, who says he wants to live forever (or die trying), and has suggested he's found the keys to immortality in stem cell research.

Some doctors agree that stem cells are a key part of chasing youth.

"If you're a wealthy guy and haven't stored your stem cells, I think you're a total idiot," said Dr. Lionel Bissoon, a New York City physician who sees a number of stressed out, wealthy patients.

Related: It's expensive being rich

They usually come to him with similar problems: "Fatigue, belly fat, erectile dysfunction, tiring very quickly ... all very common with my patients from Wall Street," Bissoon said. The short-term solution to those ailments, he says, is testosterone replacement -- which is relatively affordable at a few hundred dollars a pop -- and IV nutrition.

For the long term he recommends stem cell storage, which works as a sort of rainy day insurance. The cells are extracted, preferably when the patient is on the younger side -- around 30 is said to be a good age -- and can then be used to boost an immune system or help to rebuild damaged organs later.

Dr. Dipnarine Maharaj stores cells at his South Florida Bone Marrow Stem Cell Transplant Institute in Boynton Beach, Fla.

Originally posted here:
Can enough money buy you eternal youth?

StemGenex Announces New Stem Cell Clinical Study for Multiple Sclerosis

La Jolla, CA (PRWEB) June 17, 2014

StemGenex, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases, today announced their newest clinical study for Multiple Sclerosis. StemGenex believes that a commitment to the safety and efficacy of stem cell therapy are paramount when providing care to patients with life threatening diseases.

This clinical study is bringing to the field a new, unique type of stem cell therapy that has the possibility of being more effective than other stem cell treatments currently available. Patients who receive stem cell treatment through StemGenex for Multiple Sclerosis will receive StemGenex multiple administration protocol. This consists of four targeted administration methods of the stem cells to deliver the necessary amount of stem cells past the blood brain barrier.

Principal Investigator Dr. Jeremiah McDole, Ph.D. stated, "Currently available drugs for multiple sclerosis do not halt disease progression or aid in the repair of established damage. We strive to provide regenerative medicine applications that address this critical, underlying issue. While patients experience positive clinical outcomes as a result of stem cell treatment, large, rigorously performed studies are desired in order to guide our best efforts for future development. The study we are conducting is designed to provide us with this essential data."

This study is registered through The National Institutes of Health which can be found at http://www.clinicaltrials.gov and is being conducted under IRB approval. According to StemGenex Director of Patient Advocacy, Joe Perricone, It is important patients have access to top-tier stem cell treatment. By providing access to registered clinical studies through The National Institutes of Health, we are providing patients with the ability to choose a stem cell treatment center with the highest standard of care.

Rita Alexander, founder and president of StemGenex, stated, This is the first of many stem cell clinical studies to come and a positive step for the more than 2 million people around the world suffering with Multiple Sclerosis. The average lifetime cost of current standard of care treatment per MS patient is $1.2 million. The human cost of the disease including pain and suffering endured by MS patients, the profound impact on families and the loss of their ability to contribute to society is without question immeasurable. Dr. McDoles research background in neuroimmunology is certainly an asset in our effort to change the course of neurological diseases.

Stem cell treatment studies are currently being offered by StemGenex to patients diagnosed with Multiple Sclerosis and other degenerative neurological diseases. StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative neurological diseases including Parkinsons and Alzheimers disease, stroke recovery and others.

To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact(at)stemgenex(dot)com

Follow this link:
StemGenex Announces New Stem Cell Clinical Study for Multiple Sclerosis

Embryonic Stem Cells Offer Promising Treatment For Multiple Sclerosis

June 17, 2014

Image Caption: ImStem Biotechnologys Xiaofang Wang, seated, and Ren-He Xu. Credit: Tina Encarnacion/UConn

University of Connecticut

Scientists in the University of Connecticuts Technology Incubation Program have identified a novel approach to treating multiple sclerosis (MS) using human embryonic stem cells, offering a promising new therapy for more than 2.3 million people suffering from the debilitating disease.

The researchers demonstrated that the embryonic stem cell therapy significantly reduced MS disease severity in animal models, and offered better treatment results than stem cells derived from human adult bone marrow.

The study was led by ImStem Biotechnology Inc. of Farmington, Conn., in conjunction with UConn Health Professor Joel Pachter, Assistant Professor Stephen Crocker, and Advanced Cell Technology (ACT) Inc. of Massachusetts. ImStem was founded in 2012 by UConn doctors Xiaofang Wang and Ren-He Xu, along with Yale University doctor Xinghua Pan and investor Michael Men.

The cutting-edge work by ImStem, our first spinoff company, demonstrates the success of Connecticuts Stem Cell and Regenerative Medicine funding program in moving stem cells from bench to bedside, says Professor Marc Lalande, director of the UConns Stem Cell Institute.

The research was supported by a $1.13 million group grant from the state of Connecticuts Stem Cell Research Program that was awarded to ImStem and Professor Pachters lab.

Connecticuts investment in stem cells, especially human embryonic stem cells, continues to position our state as a leader in biomedical research, says Gov. Dannel P. Malloy. This new study moves us one step closer to a stem cell-based clinical product that could improve peoples lives.

The researchers compared eight lines of adult bone marrow stem cells to four lines of human embryonic stem cells. All of the bone marrow-related stem cells expressed high levels of a protein molecule called a cytokine that stimulates autoimmunity and can worsen the disease. All of the human embryonic stem cell-related lines expressed little of the inflammatory cytokine.

Read more:
Embryonic Stem Cells Offer Promising Treatment For Multiple Sclerosis

ReNeuron well set after 'transformational' year

ReNeuron Group Quote more

Price: 2.85

Chg: -0.17

Chg %: -5.47%

Date: 12:02

Stem cell treatment developer ReNeuron lost an increased 7.1m in a "transformational" year to end-March but still had plenty of cash in the bank as it moves into new cell manufacturing facility and files an investigational new drug (IND) application in the US early next year.

The AIM-listed company held cash outflow from operating activities roughly flat at 6m over the period, leaving cash, cash equivalents and bank deposits at period end of 20.92m, thanks to the 23.44m net fundraising in August 2013.

Chairman Bryan Morton said it was a transformational year for the business, both operationally and financially, as its lead stem cell therapy candidate for stroke entered Phase II clinical trials and the company began clinical development of a candidate for critical limb ischaemia.

He also noted that in both cases, and earlier-than-planned, ReNeuron gained regulatory approval to use a cryopreserved variant of its lead 'CTX' stem cell product line, which gives the treatments the potential to have "significant commercial and competitive advantages".

He confirmed the move to new cell manufacturing facility in South Wales early next year was on track, "which we believe will become a major element of ReNeurons overall value proposition".

Follow this link:
ReNeuron well set after 'transformational' year

KC area company developing stem cell treatments for pooches

KANSAS CITY, KS (KCTV) -

A KCK company is developing a stem cell treatment to help dogs deal with crippling pain from arthritis.

Aratana Therapeutics is working to treat osteoarthritis in pets via the stem cell treatment.

If the U.S. Food and Drug Administration approves, it would be the first treatment of its kind.

The treatment wouldn't provide a cure but would give much-needed relief.

"They're still able to move better but they can't do the things they did when they were younger," dog owner Rachel Thieme said.

Osteoarthritis can be quite debilitating for canines.

"It's really tough because may be there are other areas of quality of life that are fine. They are eating fine. They have that motivation but they just can't physically do anything, so sometimes you have to euthanize them," Thieme said.

The only way to cure the condition is to conduct a total joint replacement.

But the stem cell procedure hopefully will reduce the need for medications and therapies, said Kara Forsee, a veterinary surgeon for BluePearl Veterinary Partners.

See original here:
KC area company developing stem cell treatments for pooches

Stem Cell Doctor at Beverly Hills Orthopedic Institute Now Offering Regenerative Procedures for Achilles Tendonitis …

Beverly Hills, CA (PRWEB) June 16, 2014

The top stem cell doctors at Beverly Hills Orthopedic Institute are now offering regenerative medicine procedures for Achilles tendonitis and tears. The procedures include options for several types of stem cell procedures that can provide pain relief and help patients avoid surgery. Call (310) 438-5343 for more information and scheduling.

Achilles tendonitis or tears may bother patients for many months and not respond well to traditional treatments. This may include NSAIDS, bracing and steroid injections. While surgery for these conditions may be extremely successful, there is often a considerable rehabilitation and potential surgery complications.

Stem cell injections for Achilles tears or tendonitis have been a revolutionary treatment. This may include bone marrow derived injections, or amniotic derived stem cell procedures. Both offer exceptional concentrations of stem cells, growth factors and additional reparative materials.

The procedures are performed as an outpatient, with the amniotic derived material coming from consenting donors after scheduled c-sections. There is no fetal material used, negating any ethical concerns.

Dr. Raj at Beverly Hills Orthopedic Institute is a Double Board Certified orthopedic doctor. He treats patients from weekend warriors to amateur and professional athletes, along with celebrities, executives, manual laborers and grandparents.

For more information and scheduling, call (310) 438-5343.

Follow this link:
Stem Cell Doctor at Beverly Hills Orthopedic Institute Now Offering Regenerative Procedures for Achilles Tendonitis ...

Systematic review

Background

Relapsed multiple myeloma has no standard treatment, and the role of autologous stem-cell transplantation (ASCT) has not been fully defined. We aimed to compare high-dose melphalan plus salvage ASCT with cyclophosphamide in patients with relapsed multiple myeloma who had previously undergone ASCT.

Between April 16, 2008, and Nov 19, 2012, 297 patients were registered, of whom 293 received PAD re-induction therapy. Between Aug 26, 2008, and Nov 16, 2012, 174 patients with sufficient PBSCs were randomised to salvage ASCT (n=89) or cyclophosphamide (n=85). After a median follow-up of 31 months (IQR 1942), median time to progression was significantly longer in the salvage ASCT than in the cyclophosphamide group (19 months [95% CI 1625] vs 11 months [912]; hazard ratio 036 [95% CI 025053]; p<00001). Frequently reported (in >10% of patients) grade 34 adverse events with PAD induction, salvage ASCT, and cyclophosphamide were: neutropenia (125 [43%] of 293 patients after PAD, and 63 [76%] of 83 patients in the salvage ASCT group vs 11 [13%] of 84 patients in the cyclophosphamide group), thrombocytopenia (150 [51%] after PAD, and 60 [72%] vs four [5%], respectively), and peripheral neuropathy (35 [12%] after PAD, and none vs none, respectively).

This study provides evidence for the improved efficacy of high-dose melphalan plus salvage ASCT when compared with cyclophosphamide in patients with relapsed multiple myeloma eligible for intensive therapy, which might help to guide clinical decisions regarding the management of such patients.

Read the original here:
Systematic review